Seres Therapeutics (MCRB) Set to Post Quarterly Earnings on Wednesday

Seres Therapeutics (NASDAQ:MCRB) is expected to issue its Q3 2026 results before the market opens on Wednesday, November 4th. Analysts expect the company to announce earnings of ($1.0050) per share and revenue of $6.35 million for the quarter. Parties can check the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 8:30 AM ET.

Seres Therapeutics (NASDAQ:MCRB) last issued its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $0.47 EPS for the quarter, beating analysts’ consensus estimates of ($2.18) by $2.65. The company had revenue of $0.74 million for the quarter, compared to analyst estimates of $0.18 million. On average, analysts expect Seres Therapeutics to post ($6.33) EPS for the current fiscal year and ($2.06) EPS for the next fiscal year.

Seres Therapeutics Price Performance

Shares of MCRB stock opened at $1.80 on Wednesday. The stock’s 50 day simple moving average is $3.78 and its 200 day simple moving average is $7.40. Seres Therapeutics has a twelve month low of $1.70 and a twelve month high of $29.98.

Analyst Upgrades and Downgrades

MCRB has been the topic of several analyst reports. Weiss Ratings downgraded Seres Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, September 18th. Wall Street Zen upgraded shares of Seres Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 8th. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $17.00.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc is a biotechnology company focused on developing live biotherapeutic products designed to restore the function of the human microbiome. The company’s platform uses defined communities of microorganisms rather than conventional fecal material to address diseases associated with microbiome disruption.

Seres’ lead product, VOWST (fecal microbiota spores, live-brpk), was approved by the U.S. Food and Drug Administration in 2023 to prevent the recurrence of Clostridioides difficile infection in adults following antibacterial treatment.